Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T cells + cytotoxic T lymphocytes + dendritic cell vaccine (Shenzhen Geno-Immune Medical Institute, f10644)
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
This combination immunotherapy regimen is a multi-component cellular therapy developed by the Shenzhen Geno-Immune Medical Institute for the treatment of neurofibromatosis and schwannomatosis. The regimen integrates three distinct immunological approaches: antigen-specific Chimeric Antigen Receptor T (CAR-T) cells, engineered immune effector (EIE) cytotoxic T lymphocytes (CTLs), and an immune-modified dendritic cell vaccine (DCvac). The CAR-T cells and CTLs are designed to provide direct, targeted cytotoxicity against tumor cells, while the DCvac is intended to prime the patient's endogenous immune system and stimulate a broader T-cell response against tumor-associated antigens. The cells are modified with immunoregulatory genes to enhance their persistence and anti-tumor activity within the often immunosuppressive microenvironment of neurofibromas and schwannomas.
- Other names
- Antigen-specific T cells CART/CTL and DCvacEIE + DCvacImmunotherapy Targeting Neurofibromatosis or Schwannomatosis
02
Targets
Beyond the preview
Go deeper on CAR-T cells + cytotoxic T lymphocytes + dendritic cell vaccine (Shenzhen Geno-Immune Medical Institute, f10644).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T cells + cytotoxic T lymphocytes + dendritic cell vaccine (Shenzhen Geno-Immune Medical Institute, f10644).